Informační systém MU
KÝR, Michal, Peter MÚDRY, Kristýna POLÁŠKOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Regina DEMLOVÁ, Jana KUBÁTOVÁ, Eva HLAVÁČKOVÁ, Kateřina ČERNÁ PILÁTOVÁ, Pavel MAZANEK, Klára VEJMĚLKOVÁ, Vítězslav DUŠEK, Pavel TINKA, Martin BALÁŽ, Tomáš MERTA, Zuzana KUTTNEROVÁ, Terézia TUREKOVÁ, Zdeněk PAVELKA, Petra POKORNÁ, Hana PÁLOVÁ, Marie MLNAŘÍKOVÁ, Marta JEŽOVÁ, Renata KELLNEROVÁ, Sarka KOZAKOVA, Ondřej SLABÝ, Dalibor VALÍK and Jaroslav ŠTĚRBA. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients. International journal of cancer. HOBOKEN: WILEY, 2024, 12 pp. ISSN 0020-7136. Available from: https://dx.doi.org/10.1002/ijc.35062.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
Authors KÝR, Michal, Peter MÚDRY, Kristýna POLÁŠKOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Regina DEMLOVÁ, Jana KUBÁTOVÁ, Eva HLAVÁČKOVÁ, Kateřina ČERNÁ PILÁTOVÁ, Pavel MAZANEK, Klára VEJMĚLKOVÁ, Vítězslav DUŠEK, Pavel TINKA, Martin BALÁŽ, Tomáš MERTA, Zuzana KUTTNEROVÁ, Terézia TUREKOVÁ, Zdeněk PAVELKA, Petra POKORNÁ, Hana PÁLOVÁ, Marie MLNAŘÍKOVÁ, Marta JEŽOVÁ, Renata KELLNEROVÁ, Sarka KOZAKOVA, Ondřej SLABÝ, Dalibor VALÍK and Jaroslav ŠTĚRBA.
Edition International journal of cancer, HOBOKEN, WILEY, 2024, 0020-7136.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.400 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/ijc.35062
UT WoS 001260796700001
Keywords in English cancer vaccine; immunotherapy; metronomic chemotherapy; N-of-1; rare cancer
Tags 14110114, 14110230, 14110321, 14110513, 14110516, 14110616, 14119710
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 12/7/2024 10:25.
Abstract
A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents.
Links
LM2023049, research and development projectName: Český národní uzel Evropské sítě infrastruktur klinického výzkumu
Investor: Ministry of Education, Youth and Sports of the CR
LX22NPO5102, research and development projectName: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)
Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES
MUNI/A/1395/2022, interní kód MUName: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“
Investor: Masaryk University
MUNI/A/1625/2023, interní kód MUName: Personalizovaná léčba v dětské onkologii: na cestě k „liquid dynamic medicine“ a „N-of-1 clinical trials“
Investor: Masaryk University, Personalyzed treatment in pediatric oncology: on the way to liquid dynamic medicine and N-of-1 trials
NV19-03-00562, research and development projectName: Využití globálních metylačních profilů a komplexní analýzy fúzních genů pro terapeutické plánování v dětské onkologii
Investor: Ministry of Health of the CR
Displayed: 18/7/2024 11:35